Observe Medical ASA: Extraordinary general meeting held on 3 July 2025

03 Jul 2025 15:01 CEST

Oslo, 3 July 2025

Reference is made to the stock exchange announcement by Observe Medical ASA
("Observe Medical" or the "Company", OSE ticker: OBSVR)) on 12 June 2025,
regarding notice of an extraordinary general meeting in connection with, inter
alia, a private placement (including a loan conversion to be completed by
Navamedic ASA) and a contemplated subsequent offering in the Company.

The extraordinary general meeting was held today, on 3 July 2025, at 14:00 hours
(CEST).

All resolutions proposed by the Company's board of directors were approved,
including (i) the issuance of 56,890,000 new shares to complete the private
placement announced by the Company on 11 June 2025, (ii) the issuance of
10,000,000 new shares to Navamedic ASA in connection with their loan conversion
(such loan conversion being a part of the aforementioned private placement),
(iii) granting the board of directors an authorisation to increase the Company's
share capital by up to NOK 10,080,000 in connection with the contemplated
subsequent offering, and (iv) granting the board of directors a general
authorisation to increase the Company's share capital by up to NOK 7,740,465.60
in order to finance further growth etc.

A detailed description of the subsequent offering, including the terms and
conditions, as well as factors to consider when subscribing for shares in the
subsequent offering, will be disclosed in an offer and listing prospectus to be
published before the subscription period for the subsequent offering begins. It
is expected that the subscription period for the subsequent offering will last
from on or about 17 September 2025 at 09:00 to 1 October 2025 at 16:30, provided
that the prospectus for the subsequent offering is approved in time.

The minutes from the extraordinary general meeting are enclosed hereto and will
also be available on the Company's website www.observemedical.com/investor
-relations.

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical:

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialisation of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.

This information is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site

650674_Observe_Medical_ASA_EGM_Minutes_03_July_2025.pdf